0I3I Stock Chart & Stats
$71.78
$1.11(1.57%)
At close: 4:00 PM EDT
$71.78
$1.11(1.57%)
Day’s Range― - ―
52-Week Range$57.64 - $89.11
Previous CloseN/A
Volume88.00
Average Volume (3M)686.00
Market Cap
$14.86B
Enterprise Value$14.59K
Total Cash (Recent Filing)$138.80M
Total Debt (Recent Filing)$2.46B
Price to Earnings (P/E)63.6
Beta1.01
Next Earnings
Sep 09, 2026EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.18
Shares Outstanding195,030,620
10 Day Avg. Volume532
30 Day Avg. Volume686
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$78.00Price Target Upside8.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)4.63
Revenue Forecast (FY)$4.31B
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth And Global Contact-lens LeadershipSustained top-line expansion and leading share in contact lenses indicate durable demand, scale advantages and broad distribution. This supports resilience in the core business while giving Cooper a platform to commercialize new lens products.
Growth From Myopia Control And Fertility ProductsGrowth in myopia control and fertility broadens Cooper's product portfolio beyond mature categories. These specialized offerings can strengthen customer relationships, improve mix and support multi-year expansion in healthcare markets.
Solid Balance Sheet With Improving LeverageA substantial equity base and moderate leverage provide financial flexibility for investment, product development and strategic options. Lower net debt also reduces balance-sheet risk as the company manages litigation payments and operating volatility.
Bears Say
Recent Deterioration In Profitability And Free-cash-flow QualityMargin compression and weaker cash conversion reduce confidence in near-term earnings quality. If cost, inventory and operating pressures persist, Cooper may have less internally generated cash for investment, debt reduction and shareholder returns.
Large Fertility-business Litigation LiabilityThe settlement creates a significant cash obligation and separates GAAP results from non-GAAP performance. Concentrated payouts can constrain capital allocation and weaken financial flexibility even if underlying operations remain sound.
Persistent Asia-Pacific WeaknessWeakness in major APAC markets, combined with legacy-product rationalization and consumer softness, can pressure regional growth for several quarters. Prolonged underperformance would weigh on scale, mix and the pace of consolidated revenue expansion.
Cooper Co News
0I3I FAQ
What was Cooper Co’s price range in the past 12 months?
Cooper Co lowest share price was $57.64 and its highest was $89.11 in the past 12 months.
What is Cooper Co’s market cap?
Cooper Co’s market cap is $14.86B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Sep 09, 2026 which is in 22 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Jun 04, 2026. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.104 by $0.106.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Undervalued.
Does Cooper Co pay dividends?
Cooper Co pays a Semiannually dividend of $0.009 which represents an annual dividend yield of N/A. See more information on Cooper Co dividends here
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 1.12.
How many shares outstanding does Cooper Co have?
Cooper Co has 195,030,620 shares outstanding.
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of $1.21 in its last earnings report, beating expectations of $1.104. Following the earnings report the stock price went up 7.633%.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in GB:0I3I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.00 (8.67% Upside)
$78.00 (8.67% Upside)
Blogger Sentiment
Bullish
GB:0I3I Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
0I3I Company Deck
0I3I Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.View all GB:0I3I earnings summaries0I3I Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
0I3I Stock 12 Month Forecast
Average Price Target
$78.00
▲(8.67% Upside)